Institution

IRCCS Humanitas Research Hospital

Rozzano, ItalyWebsite

Also known as: Istituto Clinico Humanitas IRCCS

265running trials
160closed trials
25,131publications (OpenAlex)

Running trials

Not yet recruiting
Relugolix in Patients With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.
NCT07927777· Phase 3· Istituto Oncologico Veneto IRCCS· Source
Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175· Phase 2· Aimmune Nestlé Health Science US R&D, LLC· Source
Not yet recruiting
Nutritional Supplementation to Improve Colorectal Cancer Surgery
NCT07599501· Istituto Clinico Humanitas· Source
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07771465· Phase 3· Kardigan, Inc.· Source
Recruiting
Photon-Counting Computed Tomography-Based Urethral Visualization Without Catheterization for Radiotherapy Planning: A Prospective Pilot Study Under ANTHEM
NCT07730203· Istituto Clinico Humanitas· Source
Not yet recruiting
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
2025-522084-15-00· Phase 2/3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting
REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors
NCT07635641· Istituto Clinico Humanitas· Source
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328· Phase 1· Eli Lilly and Company· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases.
NCT07577115· Istituto Clinico Humanitas· Source
Recruiting
Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA
NCT07413523· Istituto Clinico Humanitas· Source
Recruiting
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723· Phase 2/3· Kardigan, Inc.· Source
Not yet recruiting
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
NCT07207785· Phase 2· Fondazione Italiana Linfomi - ETS· Source
Not yet recruiting
Postoperative Outcomes of Single-stapled Anastomosis Combined With Transanal Natural Orifice Specimen Extraction
NCT07358247· Istituto Clinico Humanitas· Source
Not yet recruiting
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
NCT07381777· Phase 2· Gruppo Oncologico Italiano di Ricerca Clinica· Source
Recruiting
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
NCT07485296· Phase 2· Gruppo Oncologico del Nord-Ovest· Source
Enrolling by invitation
SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study
NCT07116668· SafeHeal Inc· Source
Not yet recruiting
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
NCT07336641· Fondazione ISIDE· Source
Recruiting
Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial
NCT07299357· Istituto Clinico Humanitas· Source
Recruiting
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
NCT07330245· AstraZeneca· Source
Recruiting
Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss Treatment
NCT07393360· Pharmanutra S.p.a.· Source
Recruiting
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
NCT07137598· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· Phase 3· Amgen· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Recruiting
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer
NCT07389265· Phase 3· University of Campania Luigi Vanvitelli· Source
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· Phase 1/2· BioNTech SE· Source
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798· Phase 2· Amgen· Source
Recruiting
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
NCT07073079· AbbVie· Source
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)
NCT06790251· F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore· Source
Recruiting
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· Phase 2· Pfizer· Source
Recruiting
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
NCT06994143· Phase 1· Cullinan Therapeutics Inc.· Source
Enrolling by invitation
p-PHOTOLARYNX- ANTHEM: Photon-Counting CT in Laryngeal Cancer Staging
NCT07603167· Humanitas University· Source
Recruiting
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
NCT06462963· European Organisation for Research and Treatment of Cancer - EORTC· Source
Recruiting
PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
NCT06949254· Istituto Clinico Humanitas· Source
Active, not recruiting
Racial Disparities in Acute Stroke
NCT06955442· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source
Active, not recruiting
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23)
NCT05605899· Phase 3· Kite Pharma Inc.· Source
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· Phase 3· Daiichi Sankyo· Source
Recruiting
Photon-counting CT Scan vs Standard HRCT Scan in the Identification of Idiopathic Pulmonary Fibrosis
NCT07790614· Istituto Clinico Humanitas· Source
Active, not recruiting
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
NCT06716814· Phase 3· Swedish Orphan Biovitrum· Source
Not yet recruiting
Effects of Action Observation Training and Motor Imagery Delivered by Telerehabilitation in Patients with Parkinson's Disease
NCT06814782· Istituto Clinico Humanitas· Source
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
NCT06717126· Phase 2· iOnctura· Source

Showing 50 of 265.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Colorectal cancer19 recruiting
Lung cancer16 recruiting
Prostate cancer12 recruiting
Childhood cancers10 recruiting
Gastric and oesophageal cancer10 recruiting
Head and neck cancer8 recruiting
Metastatic breast cancer6 recruiting
Sarcoma6 recruiting
Bladder cancer4 recruiting
Crohn's disease4 recruiting
Liver and biliary tract cancer4 recruiting
Pancreatic cancer4 recruiting
Rheumatoid arthritis4 recruiting
Endometrial cancer3 recruiting
Glioblastoma3 recruiting
Haemophilia3 recruiting
Ovarian cancer3 recruiting
Stroke3 recruiting
Acute myeloid leukaemia2 recruiting
Asthma2 recruiting
Brain metastases2 recruiting
Bronchiectasis2 recruiting
Dermatomyositis and polymyositis (myositis)2 recruiting
Dilated cardiomyopathy2 recruiting
Fatty liver disease (MASLD/MASH)2 recruiting
Follicular lymphoma2 recruiting
Hodgkin lymphoma2 recruiting
Lupus (SLE)2 recruiting
Mantle cell lymphoma2 recruiting
Melanoma2 recruiting
Neuroendocrine tumours2 recruiting
Psoriasis2 recruiting
Triple-negative breast cancer2 recruiting
Ulcerative colitis2 recruiting
Alopecia areata1 recruiting
Amyloidosis1 recruiting
Antiphospholipid syndrome1 recruiting
Aortic stenosis1 recruiting
Atopic dermatitis (eczema)1 recruiting
Atrial fibrillation1 recruiting
Cervical cancer1 recruiting
Chronic kidney disease1 recruiting
Chronic rhinosinusitis with nasal polyps1 recruiting
Coronary artery disease1 recruiting
Cystic fibrosis1 recruiting
Cytomegalovirus infection1 recruiting
Deep vein thrombosis and pulmonary embolism1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Heart failure1 recruiting
Hidradenitis suppurativa1 recruiting
Idiopathic pulmonary fibrosis1 recruiting
IgA nephropathy1 recruiting
Immune thrombocytopenia (ITP)1 recruiting
Kidney cancer1 recruiting
Liver cirrhosis1 recruiting
Meningioma1 recruiting
Mesothelioma1 recruiting
Myocarditis1 recruiting
Obesity1 recruiting
Osteoarthritis1 recruiting
Parkinson disease1 recruiting
Primary biliary cholangitis1 recruiting
Psoriatic arthritis1 recruiting
Thyroid cancer1 recruiting
Ventricular tachycardia1 recruiting
Vitiligo1 recruiting

Closed trials

Completed
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
NCT06587451· Phase 3· H e x a l AG· Source
Completed
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A
2023-505801-17-00· Phase 1· Swedish Orphan Biovitrum AB (publ)· Source
Active, not recruiting
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
NCT06243458· Phase 2· GCP-Service International West GmbH· Source
Completed
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source
Completed
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis
2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source
Completed
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis
2023-506655-19-00· Phase 2· Genentech Inc.· Source
Completed
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.
2023-506881-30-00· Phase 1· H e x a l AG· Source
Completed
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
NCT06333860· Phase 4· AbbVie· Source
Terminated
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
NCT06241573· Phase 2/3· Boehringer Ingelheim· Source
Completed
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· Phase 3· Incyte Corporation· Source
Completed
FIH study of ALE.C04 anti-CLDN1 mAb monotherapy or in combination with pembrolizumab in patients with R/M HNSCC
2023-505145-93-00· Phase 1/2· Alentis Therapeutics AG· Source
Completed
A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source
Completed
A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy
NCT06058741· AbbVie· Source
Recruiting
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
NCT06145373· Phase 4· Sanofi· Source
Recruiting
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
NCT05934084· Fondazione Italiana Linfomi - ETS· Source
Completed
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
NCT06280391· Phase 2· Sanofi· Source
Completed
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
NCT06215586· Phase 2· Cardurion Pharmaceuticals, Inc.· Source
Completed
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306· Phase 3· Sanofi· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· Phase 2· Pfizer· Source
Completed
SafeHeal Diverting Ileostomy Pivotal Study
NCT06152276· SafeHeal Inc· Source
Withdrawn
R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT05966233· Phase 2· Fondazione Italiana Linfomi - ETS· Source
Terminated
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
NCT06039384· Phase 1· Incyte Corporation· Source
Completed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
NCT06181435· Phase 3· Sanofi· Source
Completed
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma
NCT06018129· Phase 1/2· Genmab A/S· Source
Completed
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
2023-503689-21-00· Phase 1/2· F. Hoffmann-La Roche AG· Source
Completed
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis
2022-503005-38-00· Phase 2· Landos Biopharma Inc.· Source
Completed
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
NCT06122961· Novo Nordisk A/S· Source
Completed
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source
Completed
Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer
NCT05724602· Phase 2· European Organisation For Research And Treatment Of Cancer· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043· Phase 3· Takeda· Source
Completed
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.
2022-502789-26-01· Phase 2· Agomab Spain S.L.U.· Source
Completed
Immune Microenvironment and Gene Expression Profiling in Mesothelioma
NCT06581549· Istituto Oncologico Veneto IRCCS· Source
Completed
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
NCT05882877· Phase 3· Amgen Inc.· Source
Recruiting
Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER)
2022-502060-21-00· Phase 4· Octapharma AG· Source
Completed
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017· Phase 2· Janssen Research & Development, LLC· Source
Completed
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
2022-502057-33-00· Phase 1/2· Sanofi-Aventis Recherche & Developpement· Source
Completed
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
2022-502888-38-00· Phase 2· Eli Lilly & Co.· Source
Active, not recruiting
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
NCT05909904· Phase 2· BeiGene· Source
Active, not recruiting
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
NCT05910528· Phase 2· Hoffmann-La Roche· Source
Completed
An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa
2022-502921-16-00· Phase 4· Swedish Orphan Biovitrum AB (publ)· Source
Active, not recruiting
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source
Completed
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
NCT05849922· Phase 2· Sanofi· Source
Completed
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
NCT03744468· Phase 1/2· Beigene Ltd.· Source
Completed
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580· Phase 4· AbbVie· Source
Completed
AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery Disease
NCT05471245· Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS· Source
Completed
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05767021· Phase 3· Eli Lilly and Company· Source
Completed
A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors
NCT05784597· Phase 1· Philogen S.p.A.· Source
Terminated
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
NCT05785715· Phase 2· AbbVie· Source

Showing 50 of 160.

Registry name variants (89)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Humanitas Research Hospital
Rozzano, 20089
225 trials
Istituto Clinico Humanitas
Rozzano, 20089
73 trials
IRCCS Istituto Clinico Humanitas
Rozzano, 20089
27 trials
IRCCS Humanitas Research Hospital
Rozzano, Milan 20089
18 trials
Istituto Clinico Humanitas
Milan, 20089
14 trials
Istituto Clinico Humanitas
Rozzano (MI), Lombardy 20089
7 trials
IRCCS Istituto Clinico Humanitas
Milan, 20089
6 trials
Istituto Clinico Humanitas - U.O. Ematologia
Rozzano
5 trials
IRCCS Istituto Clinico Humanitas
Rozzano MI, 20089
4 trials
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas
Rozzano, Milan 20089
4 trials
IRCCS Humanitas Research Hospital
Milan, 20089
3 trials
- NCT07927777Relugolix in Patients With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy.
  Contact: Buffi Nicolò, MD
- NCT06906094Prevention of Post mEniscectomy Osteoarthritis: From New Animal Model to Patient pRofiLing
- NCT07265414DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy
Humanitas Research Hospital IRCCS
Rozzano, 20089
2 trials
- NCT06955442Racial Disparities in Acute Stroke
- NCT05339841Italian Digital Primary Cardiovascular Prevention Study
IRCCS Humanitas Research Hospital
Rozzano MI, 20089
2 trials
- 2025-522084-15-00A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
- NCT06977581A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
IRCCS Istituto Clinico Humanitas, Cancer Center
Rozzano, 20089
2 trials
- NCT05983432Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  Contact: Matteo Simonelli
- NCT02841540A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
UOC di Endocrinologia, Diabetologia e Andrologia Medica, IRCCS Humanitas Research Hospital
Rozzano
2 trials
- NCT06790251Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)
  Contact: Maria Luisa Brandi, MD, PhD
- NCT06645951Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma
  Contact: Andrea Gerardo Antonio Lania, MD
3800056 - Istituto Clinico Humanitas
Rozzano, 20089
1 trial
- NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
Endoscopy Unit, Gastroenterology Department, Humanitas Research Hospital
Rozzano, Milano 20089
1 trial
- NCT06420843Microbiota, Metabolome and Nutrition: an 'Artificially Intelligent' Way to Personalized Nutrition
Gruppo Humanitas - Humanitas Research Hospital (Istituto Clinico Humanitas)
Rozzano, 20089
1 trial
- NCT06153693Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Humanitas Research Hospital - Medical Oncology
Rozzano, 20089
1 trial
- NCT05015010Alectinib in Neo-adjuvant Treatment of Stage III NSCLC
Humanitas Research Hospital (Site 1309)
Rozzano, Lombardy 20089
1 trial
- NCT04949256Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
Humanitas Research Hospital (Site 1600)
Rozzano, Lombardy 20089
1 trial
- NCT04662710Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
Instituto Clinico Humanitas
Milan
1 trial
- NCT06414265Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation
  Contact: Antonio Mangieri (principal investigator)
Instituto Clinico Humanitas
Rozzano, Lombardy 20089
1 trial
- NCT04394546CHAMPION-AF Clinical Trial
Instituto Clinico Humanitas
Rozzano (MI), Lombardy 20089
1 trial
- NCT02784171Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Instituto Clinico Humanitas Irccs
Rozzano, 20098
1 trial
- NCT06188702S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Humanitas University,
Rozzano, Milano
1 trial
- NCT04102774Effect of AIRVO Heated Humidification in Bronchiectasis
IRCCS Istituto Clinico Humanitas - Dermatology Unit
Rozzano, Lombardy 20089
1 trial
- NCT07336641LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
  Contact: Antonio Costanzo, MD
IRCCS Istituto clinico humanitas - Humanitas Mirasole spa
Rozzano, 20089
1 trial
- NCT06430866Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
IRCCS Istituto Clinico Humanitas /ID# 141382
Rozzano, Lombardy 20089
1 trial
- NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
IRCCS Istituto Clinico Humanitas /ID# 218560
Rozzano, Lombardy 20089
1 trial
- NCT03982394Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
IRCCS Istituto Clinico Humanitas /ID# 251275
Rozzano, Lombardy 20089
1 trial
- NCT05616871An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis
IRCCS Istituto Clinico Humanitas /ID# 251493
Rozzano, Milano 20089
1 trial
- NCT05601882A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
IRCCS Istituto Clinico Humanitas /ID# 259300
Rozzano, Lombardy 20089
1 trial
- NCT06058741A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy
IRCCS Istituto Clinico Humanitas /ID# 260801
Rozzano, Lombardy 20089
1 trial
- NCT05494606An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
IRCCS Istituto Clinico Humanitas /ID# 262991
Rozzano, Lombardy 20089
1 trial
- NCT05841537An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
IRCCS Istituto Clinico Humanitas /ID# 264463
Rozzano, Lombardy 20089
1 trial
- NCT06764693An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
  Contact: Shari Chapman
IRCCS Istituto Clinico Humanitas /ID# 268731
Rozzano, Lombardy 20089
1 trial
- NCT05930275Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
IRCCS Istituto Clinico Humanitas /ID# 274489
Rozzano, Lombardy 20089
1 trial
- NCT07073079A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
  Contact: Caterina Golotta
Istituto Clinico Humanitas /ID# 227943
Rozzano, Milano 20089
1 trial
- NCT04497597A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Istituto Clinico Humanitas - IRCCS
Milan, 20089
1 trial
- NCT03647124A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Istituto Clinico Humanitas IRCCS
Rozzano, 20089
1 trial
- NCT02832245Computerized Registry of Patients With Venous Thromboembolism (RIETE)
  Contact: Paola Ferrazzi
Istituto Clinico Humanitas (Site 1476)
Rozzano, Milano 20089
1 trial
- NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  Contact: Study Coordinator
Istituto Clinico Humanitas - U.O. di Oncologia Medica ed Ematologia
Rozzano
1 trial
- NCT03815643Avelumab Program Rollover Study
Istituto Clinico Humanitas - U.O. Ematologia
Rozzano (MI)
1 trial
- NCT03159897FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
Rozzano, Lombardy 20089
1 trial
- NCT03452137A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Medicina interna ed epatologia, Istituto clinico Humanitas
Rozzano
1 trial
- NCT05151809National Database on Primary Biliary Cholangitis
  Contact: Pietro Invernizzi, MD
Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital
Rozzano, MIlan 20089
1 trial
- NCT05935683Rhinosinusitis Italian Network: the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis
  Contact: Enrico Marco Heffler, MD, PhD
Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy
Rozzano, Milano 20089
1 trial
- NCT06625216Severe Asthma Network Italy
  Contact: Enrico Marco Heffler, MD, PhD
Università Humanitas University - Hunimed (IRCCS Istituto Clinico Humanitas - Humanitas Mirasole S.p.A.)
Rozzano
1 trial
- NCT06547827Rehabilitation With and Without Robot and Allied Digital Technologies in Stroke Patients
  Contact: Alessio Baricich
U.O di Oncologia Medica ed Ematologia, Humanitas Research Hospital
Rozzano
1 trial
- NCT05977673Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
  Contact: Francesca Ricci, MD
U.O. Ematologia - Istituto Clinico Humanitas
Rozzano, 20089
1 trial
- NCT04600804The Role of 18F-FDG-PET for Staging and Prognostication
Gruppo Humanitas - Humanitas Research Hospital - Cancer Center
Rozzano, 20089
Gruppo Humanitas - Humanitas Research Hospital (Instituto Clinico Humanitas)
Rozzano, Lombardy 20089
Gruppo Humanitas - Istituto Clinico Humanitas
Rozzano, 20089
IRCCS Instituto Clinico Humanitas
Rozzano, 20089
IRCCS Istituto Clinico Humanitas /ID# 151363
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 155626
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 155642
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 168153
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 220815
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 246630
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 256684
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 257500
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 260887
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 263466
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 263503
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 265946
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 269473
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 273566
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 274518
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas /ID# 278458
Rozzano, Lombardy 20089
IRCCS Istituto Clinico Humanitas - Rheumatology
Rozzano, 20089
Istituto Clinico Humanitas - Cancer Center (Site 0555)
Rozzano, Milano 20089
Istituto Clinico Humanitas - Humanitas Mirasole SPA
Rozzano, Milan 20089
Istituto Clinico Humanitas /ID# 147528
Rozzano, Milano 20089
Istituto Clinico Humanitas /ID# 200739
Rozzano, Milano 20089
Istituto Clinico Humanitas- IRCCS (Site 1902)
Rozzano, Milano 20089
Istituto Clinico Humanitas - Pneumologia 1
Rozzano, 20089
Istituto Clinico Humanitas, Rozzano
Milan, 20159
Istituto Clinico Humanitas Rozzano, IRCCS
Rozzano, 20089
Istituto Clinico Humanitas (Site 0398)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 0504)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 0704)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 1613)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 1803)
Rozzano, Lombardy 20089
Istituto Clinico Humanitas (Site 1808)
Rozzano, Milano 20089
Istituto Clinico Humanitas (Site 1812)
Rozzano, Milano 20089
Istituto Clinico Humanitas, UO Ematologia
Rozzano
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas
Milan, 20089

Conditions

Diseases this institution publishes on or runs trials for.

Liver and biliary tract cancer120 works · 23 trials
Colorectal cancer93 works · 32 trials
Asthma90 works · 4 trials
Prostate cancer66 works · 20 trials
Ulcerative colitis62 works · 28 trials
Bronchiectasis59 works · 6 trials
Bladder cancer48 works · 12 trials
Crohn's disease45 works · 17 trials
Pancreatic cancer40 works · 11 trials
Psoriasis36 works · 11 trials
Atopic dermatitis (eczema)34 works · 11 trials
Coronary artery disease32 works · 5 trials
Neuroendocrine tumours27 works · 5 trials
Systemic sclerosis (scleroderma)27 works · 1 trial
Chronic rhinosinusitis with nasal polyps25 works · 2 trials
Sarcoma25 works · 11 trials
Myelodysplastic syndromes20 works · 13 trials
Primary biliary cholangitis19 works · 3 trials
Haemophilia17 works · 8 trials
Aortic stenosis16 works · 1 trial
Psoriatic arthritis16 works · 5 trials
Hodgkin lymphoma15 works · 8 trials
Eosinophilic oesophagitis13 works · 3 trials
Head and neck cancer12 works · 19 trials
Mesothelioma11 works · 8 trials
Dilated cardiomyopathy9 works · 3 trials
Thymoma and thymic carcinoma9 works · 0 trials
Myocarditis9 works · 1 trial
Peripheral artery disease7 works · 1 trial
Alopecia areata7 works · 3 trials

Institution data: ROR 05d538656 (CC0-1.0)Updated 14 Nov 2026

Report an error